Found 89 results
Filters: Keyword is Humans  [Clear All Filters]
Lee YSun, Kulkarani V, Cowell SM, Ma S-W, Davis P, Hanlon KE, Vanderah TW, Lai J, Porreca F, Vardanyan R et al..  2011.  Development of potent μ and δ opioid agonists with high lipophilicity.. J Med Chem. 54(1):382-6.
Yamamoto T, Nair P, Largent-Milnes TM, Jacobsen NE, Davis P, Ma S-W, Yamamura HI, Vanderah TW, Porreca F, Lai J et al..  2011.  Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.. J Med Chem. 54(7):2029-38.
Zhao L, Mao Z, Schneider LS, Brinton RD.  2011.  Estrogen receptor β-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause.. Menopause. 18(10):1131-42.
North American Menopause Society.  2011.  The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010).. Menopause. 18(7):732-53.
Yao J, Rettberg JR, Klosinski LP, Cadenas E, Brinton RDiaz.  2011.  Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions.. Mol Aspects Med. 32(4-6):247-57.
Vardanyan R, Kumirov VK, Nichol GS, Davis P, Liktor-Busa E, Rankin D, Varga E, Vanderah T, Porreca F, Lai J et al..  2011.  Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.. Bioorg Med Chem. 19(20):6135-42.
Yao J, Brinton RDiaz.  2011.  Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment.. Curr Pharm Des. 17(31):3474-9.